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                                                         ABSTRACT 
 
Plahovinsak, Jennifer.  M.S., Department of Pharmacology and Toxicology, Wright State 
University, 2006.  Kinetics and Passive Protection Efficacy Induced by Purified AVA 
Human Immunoglobulin G in Rabbits Against a Bacillus anthracis Aerosol Challenge. 
 
 
The present study was conducted to determine the half-life, assess the toxicity, 
and passive protection efficacy of purified immunoglobulin G (IgG) from Anthrax 
Vaccine Adsorbed (AVA) vaccinated human donors.  Half-life determinations were 
calculated from the reportable values obtained using the anti-PA ELISA assay and the 
Centers for Disease Control’s (CDC) “ELISA for Windows” software.  For toxicity 
evaluations animals were observed clinical for one hour post administration and for 14-
days post-treatment.  The protection efficacy was determined based upon the mortality 
results from a lethal Bacillus anthracis aerosol challenge.  While no protection was 
achieved in this delayed exposure scenario, the study yielded valuable kinetics data for use 
in future research.
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INTRODUCTION 
 
Background 
 
Bacillus anthracis, the etiologic agent of anthrax is a gram-positive, rod-shaped, 
facultative aerobic, spore forming bacterium.  B. anthracis causes the human disease 
anthrax with different clinical manifestations after introduction by gastrointestinal, 
cutaneous, or pulmonary routes.  The bacterial incubation period varies from 12 h to 5 
days depending upon the dose, but the onset may be longer following inhalational 
exposure (Dixon et al, 1999).  Anthrax introduced by inhaling B. anthracis spores has the 
highest mortality rate.  Following a low spore exposure or cessation of therapeutic 
intervention (e.g. antibiotics), some reports suggest a delayed disease onset of several 
weeks (Phipps et al, 2004).  The initial clinical signs and symptoms  upon inhalation of B. 
anthracis spores are non-specific and may include malaise, headache, fever, nausea, and 
vomiting.  Initial clinical signs are followed by a sudden onset of respiratory distress with 
dsypnea, stridor, cyanosis, and chest pain.  The onset of respiratory distress is followed 
by shock and death with close to 100% mortality (Inglesby et al, 2002). 
 Anthrax is considered a serious terrorist and military threat due to the durability 
of B. anthracis spores and the high mortality from inhalational exposure.  Three 
genetically different strains of B. anthracis have been identified; Ames, Vollum, and 
Sterne.  The bacterium commonly exists in two different states, the vegetative and the 
spore forms.  The vegetative cell is the active state of the bacterium, whereas the spore is 
the dormant state in which, under a myriad of conditions, the bacterium can hibernate for 
decades.  Vegetative cells have characteristic squared ends and form chains.  In a host, 
spores only germinate and multiply in the presence of the required substrates (i.e. amino 
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acids, nucleosides, glucose, etc) (Lew 2000).  The endospores are located centrally in the 
vegetative cell’s sporangium.  The spores are resistant to extreme conditions including 
temperature variations, radiation, and desiccation.  Microscopically, the spores are 
resistant to gram staining and are highly refractive to light (Dixon et al, 1999).   
Expression of a poly-D-glutamic acid capsule and a tripartite exotoxin are 
essential for virulence of B. anthracis (Ezzel & Welkos, 1999).  The Sterne strain lacks 
the polypeptide capsule rendering it non-virulent.  The polypeptide capsule helps the 
bacterium evade phagocytosis by macrophages, while three secreted protein subunits  
form the exotoxin.  The three secreted exotoxin proteins are Protective Antigen (PA), 
Lethal Factor (LF), and Edema Factor (EF), which combine to form two distinct toxins: 
lethal toxin (LT) formed by PA and LF, and Edema Toxin (ET) formed by PA and EF.     
The PA subunit binds to one of two cell-surface receptors, capillary 
morphogenesis protein 2 (CMG2) or anthrax toxin receptor/tumor endothelial markers 8 
(ATR/TEM 8).  Both receptors are membrane spanning, single peptide chains with an 
extra cellular von Willebrand factor A (VWA) domain, and a cytoplasmic tail.  The 
VWA domain fold, a site for dinucleotide binding, is ubiquitously located in many cell 
adhesion proteins and promotes protein-protein interactions (Lacy et al, 2004).  These 
interactions promote the binding of the PA.  These two receptors appear to be expressed 
in many different cell types (Scobie and Young, 2005).   
The PA subunits  are 83 kilodaltons (kDa) in size and bind to host cells via the 
membrane bound Anthrax Toxin Receptor.  The 83 kDa PA is cleaved by furin to form a 
63 kDa PA subunit.  The PA subunits once cleaved, combine to form heptamers.  The 
dissociation of the smaller fragment allows for the larger fragment, which remains 
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receptor bound, to self associate into a ring shape, also referred to as a prepore. The 
prepore results in the exposure of a binding site where up to three molecules of LF and 
EF compete for binding (Abrami et al, 2005).  The binding of the heptameric PA to LF or 
EF forms LT and ET respectively, in which the LT or ET are internalized by the cells via 
receptor mediated phagocytosis/endocytosis.  Following internalization heptameric PA 
forms a channel in the phagosome/endosome which allows the toxic LF and EF subunits 
access to the cell cytoplasm (Welkos et al, 2001).  It is generally accepted that LF is a 
protease, which inactivates mitogen-activated protein kinase kinase 1 (MAPKK1) and 
MAPPK 2, which in turn inactivates the MAPK signal transduction pathway.  EF is a 
calcium-dependent adenylate cyclase that inhibits phagocytosis (Scobie & Young, 2005). 
Figure 1.  B. anthracis Binding Pathway 
http://www.biotechjournal.com/Pathways/anthrax.htm 
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It has been theorized that LT and ET contribute to the bacteria’s ability to evade 
the host innate immune response, possibly by inducing apoptosis in activated 
macrophages, inhibiting phagocytosis, and deregulating proinflammatory cytokines 
(Phipps et al, 2004).  These processes may allow the bacteria to multiply rapidly leading 
to an exponential increase in toxin production.  LT and ET are likely efficacious targets 
for current therapeutic interventions and possible novel interference approaches.       
 
Current Treatments 
Licensed products for the prevention or treatment of anthrax include the vaccine 
Biothrax produced by Bioport (Lansing, Michigan; also known as Anthrax Vaccine 
Adsorbed, AVA) and antibiotics (described below).  Limited clinical studies for Biothrax 
have reported higher than normal adverse reactions at local injection sites in females 
versus males (Joellenbeck et al, 2002).  In addition to inconsistent reactions to the 
vaccine, the scientific basis for the recommended vaccination schedule of six 
subcutaneous vaccinations is unclear (Wang and Roehrl, 2005).  The significant 
immunogen in all effective vaccines against anthrax is based upon the PA component of 
the anthrax toxin, although the mechanism leading to protection is unclear.  While PA is 
the major component of the AVA, there are several other unquantified components in the 
vaccine preparation (McBride et al, 1998).  Public skepticism also exists regarding the 
credibility of the limited animal data and the efficacy of the vaccine against an 
inhalational challenge (Ivins et al, 1998).  Due to the skepticism regarding the dose 
regimen, efficacy, and inconsistent adverse effects of the licensed vaccine, in 
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combination with recent civilian attacks, an interest in novel and more refined alternative 
vaccines for anthrax has developed. 
Currently, the recommended treatment regimen for inhalation anthrax exposure 
for non-vaccinated individuals centers primarily on antibiotics in combination with 
aggressive supportive care.  Several antibiotics have been licensed for use in the 
treatment of anthrax including fluroquinolones, doxycycline, and penicillin/amoxicillin.  
Fluroquinolones (ciprofloxacin or levofloxacin) inhibit DNA replication, and 
ciprofloxacin has been recommended as the drug of choice by the CDC, the Working 
Group for Civilian Biodefense, and the Department of Defense.  These recommendations 
are based upon in vitro activity against B. anthracis and in vivo efficacy demonstrated 
from the prophylaxis of inhaled anthrax.  The recommended antibiotic treatment 
following possible B. anthracis exposure is oral ciprofloxacin (500mg) twice daily for 60 
days (CDC Update: MMWR Weekly, 2001).  The long duration of antibiotic therapy is 
due to the incubation period of the spores ranging from h to several days or weeks.  
However, antibiotics are effective against killing the bacteria but are not protective 
against the deleterious effects of the toxins. The primary mechanism for the 
neutralization of the toxins is toxin specific antibodies. The large amounts of toxin 
produced by B. anthracis often send the patient into shock and the disease is often fatal 
once symptoms are recognized (Wang and Roehrl, 2005).   
The effectiveness of a biological warfare event is dependent on the susceptibility 
of the target population to the agent of choice. Due to the questions regarding the 
licensed vaccine, the long duration of antibiotic therapies, and recent civilian attacks an 
interest in novel and more refined treatments for anthrax has emerged.  Passively 
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transferred antibodies provide an innovative approach.  These antibodies are expected to 
provide immediate immunity against a biological agent regardless of the immune status 
of the host.   
 
Passive Antibody Therapy 
Passive antibody therapy was first reported in 1890 by Emil Behring and 
Shibasaburo Kitasato (Browning, 1955).  Serum was collected from rabbits immunized 
against tetanus and the serum was injected into the abdominal cavity of mice.  The treated 
mice survived a challenge of live virulent tetanus bacteria and exhibited no signs of 
infection.  This demonstrated that substances present in serum following a vaccination 
provided adequate protection against infection, and that immunity can be passively 
acquired.  Passively transferred antibodies induce a protective effect via several different 
pathways.  The antibody can mark a pathogen for opsonization by binding to bacterial 
surfaces and initiate antibody-dependent cell-mediated cytotoxicity (ADCC).  Most 
importantly the antibody induces recruitment of the complement pathway signaling the 
removal and destruction of a pathogen (Goldsby, 2001).   
 Passively administered antibodies to B. anthracis have been used in vitro and in 
vivo.  These antibodies inhibited LT toxicity to macrophages in vitro, neutralized LT 
prior to injection in rats, and protected rats by a pre-challenge intraperitoneal (IP) 
treatment of a monoclonal antibody (mAb) prior to intravenous (IV) injection of LT 
(Koblier, 2002).  Passive antibodies from varying amounts of anti-PA rabbit serum 
administered post-challenge in guinea pigs also demonstrated protective effects against a 
25 LD50 Vollum spore challenge.  However, 24 h after exposure the protective efficacy of 
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the anti-PA serum decreased.  The half life of mAb was 3-4 days and the half-life of the 
anti-PA serum was found to be 9-10 days (Koblier, 2002).  The proposed mechanism of 
passive antibody protection is the physical binding to anthrax toxin impeding the toxin’s 
interaction with the host cell receptor (Little et al, 1997).   
 Acute lethal toxicity can be observed as an adverse effect of passive 
immunization.  Animal efficacy studies did not predict the toxic response in humans 
during the development of a passive immunization with anti-meningoccal serum against 
Nesseria meningitis (meningococcus).  Toxicity in humans was observed as anaphylaxis, 
fever, chills, dyspnea, lethargy, and serum sickness, and was not observed in the animal 
studies.  Serum sickness, a syndrome resulting in malaise, rash, fever, and arthralgia 
normally occurring 7-10 days after therapy, was initiated.  The formation of immune 
complexes from host responses to the foreign proteins was the speculated cause 
(Casadevall, 1994).    In passively treated mice challenged with C. neoformans, an acute 
toxicity lead to death within 20-60 min after injection (Savoy, 1997).  Again the toxicity 
appeared to be caused by the formation of immune complexes, which activate 
macrophages.  Timing of the passive immunization in relation to the time of challenge 
was important with regards to toxicity.  The acute lethal toxicity was most evident during 
the mid-stage of the infection.  Toxicity was less evident during the early and late stages 
of infection.  Mice that survived 1 h post challenge recovered fully (Savoy, 1997).  
   A major advantage to passive antibody therapy is that it provides a state of 
immediate immunity which lasts from several weeks to potentially several months.  
Many human IgG isotypes have half-lives that exceed 30 days, which may lead to long-
lived protection for passively immunized subjects.  Immunoglobulins are extremely 
 8 
versatile molecules that can be tailored for use against virtually any infectious agent.  
One aspect that has limited the development of antibody based therapies against 
infectious agents is the recognition that efficacy is directly related to timing of 
administration.  This project, will evaluate the timing of pre-exposure administration of 
purified human IgG and the efficacy against a lethal B. anthracis challenge in rabbits.  
The proposed method of protection relies upon purified human IgG antibodies binding to 
the PA exotoxin subunit, and physically inhibiting the binding of PA to the host cell’s 
anthrax toxin receptor thus preventing the formation of LT and ET. 
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PURPOSE 
The efficacy of a treatment against B. anthracis cannot be tested in humans due to 
ethical considerations.  The results from this study will determine the clearance of the 
human IgG from the rabbit serum.  Although the human IgG will be cleared from the 
rabbit at an accelerated rate, the volume of plasma required to complete the purification 
process cannot be obtained from a single rabbit.  Post-treatment serum concentrations of 
anti-PA will be compared amongst groups to determine if a 20 mg/kg dose of purified 
AIG is sufficient to provide protection.  Clinical signs of toxicity will determine whether 
the levels of purified human antibody administered are tolerated by the rabbit.  A post 
treatment aerosol challenge will evaluate the efficacy of passively transferred AIG.   
The mortality results will yield valuable data for future research into the use of 
passive antibody administration as an immediate pretreatment for B. anthracis exposure 
and eventually as a potential prophylaxis against infection.  The delayed exposure 
scenario tested will provide the data to determine the half-life of the purified AIG 
material for use in future research.  This half-life information will be used in future 
studies to determine potential as a post-exposure treatment.  The half life of the material 
in the rabbit will provide a starting point for future research in higher species such as 
non-human primates.    
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HYPOTHESIS    
The administration of column purified plasma containing Immunoglobulin G (IgG) from 
AVA vaccinated human donors (AIG) will provide passive protection in rabbits against a 
lethal B. anthracis aerosol challenge. 
 
SPECIFIC AIMS  
1. To evaluate the pharmacokinetic parameters (i.e. half-life) of passively 
administered purified IgG using the Anti-PA Enzyme Linked Immunosorbent 
Assays (ELISA).  This assay will quantify the levels of human anti-PA present in 
the rabbit serum at 1, 24, 48, 72, 96 h, and 7, 10, 13, 16, 19, 22, 25, and 28 days 
post treatment and allow for an accurate assessment of IgG clearance from the 
rabbit serum. 
    
2. To evaluate the potential toxicity caused by passively administered purified 
human IgG using clinical observations. 
 
3. To statistically evaluate the protective efficacy of passively administered purified 
IgG to a lethal challenge of B. anthracis spores using survival data. 
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EXPERIMENTAL APPROACH   
Chemicals and reagents 
 Normal human plasma samples were received from Interstate Blood Bank 
(Chicago, IL).  AVA human plasma samples were generously provided by Cangene 
Corporation (Winnipeg, Manitoba, Canada).  0.9 % physiological saline was purchased 
from Butler Animal Health Supply (Dublin, OH).  Sterile water was purchased from 
Sigma, (St Louis, MO).  Purified rPA for plate coating was purchased from National 
Institutes of Health (NIH), (Bethesda, MD), Lot number 1715AA.   
ELISA wash buffer was prepared fresh and contained 1X Phosphate Buffered 
Saline (PBS, Sigma), with 0.1 % Tween 20 (Sigma).  ELISA Diluent was prepared fresh 
and contained 1X PBS with 5% skim milk and 0.2 % Tween 20, pH 7.4.  Master Plate 
Diluent was prepared fresh and contained 1X PBS with 5% skim milk and 0.5 % Tween 
20, pH 7.4.  Deionized water was obtained at Battelle Memorial Institute (BMI).   
Quality Control Serum High was produced at BMI, lot number BMI500.  (This is 
a high titer human serum.) Quality Control Serum Low was produced at BMI, lot number 
BMI502.  (This is a low titer human serum.)  Negative Control Serum was produced at 
BMI, Lot number 093K0475.  (This is a negative human serum).   
Naïve rabbit serum was produced at BMI, Lot number BMI012.  Positive Control 
rabbit serum was produced at BMI, Lot number BMI023.  Pooled naïve human serum 
was produced at BMI, Lot number BMI504.  Pooled AVA human serum was produced at 
BMI, Lot number BMI505.  Positive Control human serum was purchased from the 
Center for Disease Control (CDC, Atlanta, GA), Lot number ARV801.   
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HRPO Conjugate, ABTS Microwell Perioxidase Substrate System, and ABTS 
Perioxidase Stop Solution were purchased from Kirkegaard & Perry Laboratories, 
(Gaithersburg, MD).  
 
Antibody Purification 
Normal human plasma samples were received from Interstate Blood Bank and 
prescreened via ELISA (Performed at BMI, methods adapted from Quinn, et al 2002) to 
confirm the samples (1 L each) were negative for PA-specific IgG.  Upon confirmation of 
anti-PA IgG negative plasma samples, all samples were pooled into a single batch.  From 
the pooled plasma, 1 ml aliquots were removed for characterization by ELISA (to 
confirm the pooled material’s anti-PA IgG negativity).   
Similarly, the AVA human plasma samples, received from Cangene Corporation, 
were characterized by ELISA (Performed at BMI, methods adapted from Quinn, et al 
2002) for anti-PA IgG.  AVA positive plasma samples were pooled and 1 ml aliquots 
removed for ELISA reassessment of anti-PA IgG levels.  For both the naïve and AVA 
plasma pools, the plasma was re-distributed into appropriately sized aliquots and shipped 
on dry ice to Covance Research Products (CRP), (Denver, PA) for column purification of 
the IgG according to CRP Standard Operating Procedures (SOP). 
 
Passive Antibody Administration 
Forty rabbits were randomly assigned (using the MREF Animal Randomization 
Program) to five total groups:  three test groups of eight animals per group, and two 
control groups of eight animals per group (Table 1).  Each group contained equal 
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numbers of male and female rabbits (four male, four female) to eliminate any potential 
gender differences.  On Study Day 0 animals in Groups 1, 2, and 3 were administered 
anti-PA doses of AVA IgG (AIG) by the IP route as described in Table 1. Animals in 
Group 4 were IP-administered normal IgG at the same total protein dose level as the 
Group 3 animals.  The total protein for each animal was calculated by:     
Total protein (mg/kg) = Total volume (ml) x concentration (mg/ml) 
                     Weight of animal (kg) 
 
Group 5 rabbits did not receive treatment.  All study animals were weighed on 
Study Day -1 to calculate IP dose volumes.  A non-challenge AIG 20 mg/kg group was 
not included in this particular study due to the limited amount of AIG material available 
for use.   
 
Table 1. Group Descriptions Including Dose and Challenge Schedule.  
 
Group 
(n=8) 
IP Dosing 
Material Dose (mg/kg) 
B. anthracis Spore 
Inhalation Challenge 
1 AIG 5 
2 AIG 10 
None 
3 AIG 20 
4 Normal IgG Group 3 total protein dose 
5 None None 
Day 14 
 
 
B. anthracis Aerosol Challenges 
 On Day 14 the animals in the challenge groups were randomly assigned to a 
challenge order using the MREF Animal Randomization Program.  Animals in Groups 1 
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and 2 were not challenged.  Challenged rabbits were placed into a plethysmography 
chamber in a Class III Biological Safety cabinet system and challenged with aerosolized 
B. anthracis spores (Ames Strain).  Rabbits were challenged with a target dose of 200-
times the mean lethal dose (LD50), based upon the published rabbit aerosol LD50 of 1.05x 
105 colony forming units (CFU) (Zaucha et al, 1998).  The duration of the challenge was 
determined upon an estimated aerosol spore concentration and a cumulative minute 
volume gathered during the challenge.  Challenges were conducted according to BMI 
SOP’s.    
 
Clinical Observations 
Animals were observed twice daily for 14 days post-treatment (prior to challenge) 
for signs of protein toxicity.  Potential clinical signs included, but were not limited to, 
loss of appetite, respiratory distress, abnormal colored urine, weakness in back legs, loss 
of coordination, and cool to the touch (Savoy, 1997).     
 Scheduled animals were challenged (on Study Day 14) with Ames strain B. 
anthracis spores as described above, and observed post challenge for an additional 14 
days (twice daily) for signs of disease or mortality.  However, it should be noted that 
experimentally infected rabbits exhibit few, if any, signs of disease prior to the day of 
death.  Independent publications consistently report an abrupt terminal phase in lethally 
infected rabbits.  Clinical disease is not generally apparent until the day of death, at 
which time rabbits become progressively lethargic and weak.  Rabbits may exhibit brief 
periods of excitation and hyperactivity within h or min prior to death.  Symptoms may 
include: hyperactivity or seizure denoting meningitis or encephalitis; loss of coordination, 
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respiratory distress, dyspnea, or forced abdominal respirations; unresponsive to touch or 
external stimuli; and moribundity (Zaucha et al, 1998).   
 Animals determined to be moribund were euthanized.  Animals not challenged 
were euthanized on Study Day 28.  Deaths or euthanasia were recorded to the nearest 
day. 
 
Blood Collections 
Blood samples were obtained from all study animals according to the schedule in 
Table 2.  Blood was collected from the medial artery of the animals’ ears.  
Approximately 2 ml of blood was collected from all groups listed in Table 2 for the anti-
PA IgG ELISA.  Samples were collected into a Serum Separator Tubes (Becton 
Dickinson, Franklin Lakes, NJ), sterile filtered (Nalgene, Rochester, NY, PES Filters, 
0.2µm pore size, 13 mm diameter), cultured to confirm sterility according to BMI SOP’s, 
aliquoted into two cryovials (VWR, West Chester, PA) each contain approximately 300 
µl, and stored at -70º C until analyzed by ELISA for anti-PA IgG activity.   
 
Table 2. Blood Collection Schedule 
Group 
(n=8) 
IP Dosing 
Material ELISA
1 
1 AIG 
2 AIG 
3 AIG 
4 Normal IgG 
Pre-dose Baseline (Day-1) 
 
Post dosing h:1, 24, 48, 72, and 96 
 
Study Days:7, 10, 13, 16, 19, 22, 25, and 28 
1 Blood collection times are based specifically on each individual animal’s IP treatment times.   
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Anti-PA Enzyme Linked Immunosorbent Assay (ELISA) 
This assay, adapted from Quinn et al, 2001, quantifies the levels of human anti-
PA present in the rabbit serum at 1, 24, 48, 72, 96 h and 7, 10, 13, 16, 19, 22, 25, and 28 
days post-treatment allowing for assessment of normal human IgG or AIG clearance.  
The assay measures IgG antibodies against anthrax PA using an ELISA in which purified 
recombinant Protective Antigen (rPA) is used as the solid-phase immobilized antigen. 
Purified rPA for plate coating was purchased from National Institutes of Health (NIH), 
(Bethesda, MD) Lot number 1715AA.  The secondary antibody (Anti-Human HRPO 
Conjugate Lot AVR423, Kirkegaard & Perry Laboratories) was used as the reporter or 
signal system is an enzyme-conjugated anti-gamma chain.  The assay result is reported as 
the mean serum concentration of anti-PA specific IgG. 
   The primary acceptance criteria conclude whether or not the plate meets the 
required minimum standards.  If a plate failed to meet any one of the three following 
criteria the plate failed and any results were disregarded. 
1. The four parameter logistic log (4PL) curve was generated from the 
reference standard 7 point dilution must have an R2 value of =0.9800. 
2. The Quality Control samples must fall within their concentration range 
(average ± 3 standard deviations).  Quality Control Serum High, lot 
number BMI500, (High titer human serum).  Quality Control Serum Low, 
lot number BMI502, (Low titer human serum).   
3. The negative control must have a mean optical density of <0.2.  Negative 
Control Serum, Lot number 093K0475, (negative human serum).    
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The secondary acceptance criteria including the intra-assay and intra-dilution % 
coefficient of variation (CV) conclude whether or not the test sample results are 
acceptable.   
Serum samples were aliquoted into appropriate volumes (~ 300µl), and frozen at 
<-70 º C until analyzed.  Serum was not frozen and thawed more than 5 times with fewer 
freeze/thaw cycles being preferred.   
ELISA plates (Immulon 2 HB, VWR, West Chester, PA) were coated with 1.0 
µg/ml rPA (NIH, Lot 1715AA), covered with aluminum foil and incubated at 2-8º C 
overnight for at least 14 h.  Coated plates were used within 7 days or discarded.   Master 
Plate Diluent was prepared fresh and contained 1X PBS with 5% skim milk and 0.5 % 
Tween 20, pH 7.4.  ELISA buffers were warmed to room temperature, and the rPA-
coated plates were washed 3 times using an automated plate washer (Bio-Tek model 
ELx405, Winooski, VT).  ELISA wash buffer was prepared fresh and contained 1X 
Phosphate Buffered Saline (PBS, Sigma), with 0.1 % Tween 20 (Sigma).  
ELISA diluent buffer (100 µl/well) was added to all wells except column 12 
which is reserved for quality and negative controls (Figure 1.).  ELISA Diluent was 
prepared fresh and contained 1X PBS with 5% skim milk and 0.2 % Tween 20, pH 7.4.  
The serum standards were loaded into the plate wells in triplicate (columns 1-3).  The 
quality controls and negative controls were added to column 12.  The test samples were 
pre-diluted (typically 1:50) and loaded into the remaining wells.  Samples in columns 1-
11 were diluted using a two fold dilution.   
The plates were incubated for 60 min at 37ºC (Nu Aire model NU-2600, 
Plymouth, MN).  The plates were washed 3 times and 100 µl of diluted conjugate 
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solution was added to all plate wells, (Anti-Human HRPO Conjugate, Lot AVR423).  
The plates were returned to the humidified chamber to incubate for an additional 60 min.  
The plates were removed and washed 3 times and 100 µl of substrate was added to all the 
wells, (ABTS Microwell Perioxidase Substrate System, Kirkegaard & Perry 
Laboratories).  After a final incubation in the humidified chamber for 30 min, 100 µl of 
stop solution was added to the plates, (ABTS Peroxidase Stop Solution, Kirkegaard & 
Perry Laboratories).  The plates were then read within 4 h of addition of stop solution 
(Bio-Tek Plate Reader model ELx800).  The data is then transferred to the CDC’s 
“ELISA for Windows” analysis program and the reportable value calculated. 
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Table 3.  Example of Test Plate Layout for ELISA Assay. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A S1 S1 S1 TS1 TS1 TS2 TS2 TS3 TS3 TS4 TS4 QC-HIGH 
B S2 S2 S2 TS1 TS1 TS2 TS2 TS3 TS3 TS4 TS4 QC-HIGH 
C S3 S3 S3 TS1 TS1 TS2 TS2 TS3 TS3 TS4 TS4 QC-LOW 
D S4 S4 S4 TS1 TS1 TS2 TS2 TS3 TS3 TS4 TS4 QC-LOW 
E S5 S5 S5 TS1 TS1 TS2 TS2 TS3 TS3 TS4 TS4 QC-QUAL 
F S6 S6 S6 TS1 TS1 TS2 TS2 TS3 TS3 TS4 TS4 QC-QUAL 
G S7 S7 S7 TS1 TS1 TS2 TS2 TS3 TS3 TS4 TS4 NC 
H S8 S8 S8 TS1 TS1 TS2 TS2 TS3 TS3 TS4 TS4 NC 
S1-S8 = Reference Standard Serum, Dilutions 1-8 
TS# = Test Samples 1-4 
QC-HIGH = High Concentration Serum Control 
QC-LOW = Low Concentration Serum Control 
QC-QUAL = Candidate Concentration Serum Control under Qualification 
NC = Negative Serum Control 
*Note: Columns 1-3 are reference standard samples diluted serially 2-fold down the plate, and columns 4-11 are 
unknown test samples diluted serially 2-fold down the plate. 
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ELISA Pilot Study 1 
A pilot study was conducted to assess the ability of the human IgG ELISA to 
detect the purified AIG (Cov-060320-purIgG) in naïve human serum (093K0475), naïve 
rabbit serum (BMI012), anti-PA positive rabbit serum (BMI023), and PBS at a dilution 
series of expected concentrations.  The AIG test material was spiked into the diluents at 
the dilution levels listed in Table 4. All dilutions in groups 1-16 were performed in 
triplicate.   The samples were then analyzed via ELISA to determine the assay’s recovery 
of AIG material from the samples. 
 
Table 4. ELISA Pilot Study 1 Test Matrix 
Group Number Diluent AVA IgG
1 Dilution 
Factor 
1 1:10 
2 1:25 
3 1:50 
4 
Naïve Rabbit2 
1:100 
5 1:10 
6 1:25 
7 1:50 
8 
Anti-PA IgG Positive 
Rabbit3 
1:100 
9 1:10 
10 1:25 
11 1:50 
12 
Naïve Human4 
1:100 
13 1:10 
14 1:25 
15 1:50 
16 
PBS 
(control) 
1:100 
1 = AIG is the test material (Lot Cov-060320-purIgG) 
2 = Lot No. BMI012  
3 = Lot No. BMI023 
4 = Lot No. 093K0475   
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ELISA Pilot Study 2  
A second pilot study was conducted to compare the ability of the human IgG 
ELISA to detect the AIG (Cov-060320-purIgG), the AVA plasma (BMI505, source 
material for AIG), and a well characterized positive human serum (AVR801) from naïve 
human serum (093K0475), naïve rabbit serum (BMI012), and PBS at a dilution series of 
expected concentrations.  The samples were prepared by spiking the test material into the 
diluents as listed in Table 5.  All dilutions in were performed in triplicate.   The samples 
were then analyzed via ELISA to determine the assay’s recovery of AIG and AVA 
plasma, and positive human serum from the samples. 
 
Table 5.  ELISA Pilot Study 2 Test Matrix 
Diluent AIG1 AVA Plasma2 
Anti-PA IgG 
positive Human 
Serum3 
1:10 1:10 1:10 
1:25 1:25 1:25 
1:50 1:50 1:50 
Naïve Rabbit4 
1:100 1:100 1:100 
1:10 1:10 1:10 
1:25 1:25 1:25 
1:50 1:50 1:50 
Naïve Human5 
1:100 1:100 1:100 
1:10 1:10 1:10 
1:25 1:25 1:25 
1:50 1:50 1:50 
PBS 
(control) 
1:100 1:100 1:100 
1 = AIG test material (Lot Cov-060320-purIgG).  
2 = Source plasma for AIG.  (Pooled plasma from AVA vaccinated donors BMI-505). 
3 = Lot No. AVR801 
4 = Lot No.BMI012 
5 = Lot No. 093K0475 
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Statistical Analysis   
Statistical evaluations were performed in StatExat 6.0, according to BMI SOPs.  
To determine any differences between naïve human, naïve rabbit, anti-PA positive rabbit 
serum, and PBS in terms of ELISA response to AIG, a regression model was fitted to the 
data with factors for serum type, dilution factor (AIG, AVA plasma, and anti-PA positive 
human serum), and the interaction.  Separate models were fitted to each spiking material, 
slopes and intercepts were estimated for the relationship between dilution and the ELISA 
result for each diluent.  Tests were conducted to determine if the slopes and/or intercepts 
for the different serum types were significantly different from each another. 
The relationship between antibody response (measured by ELISA) and dilution of 
each spiking material (AIG, AVA plasma, and anti-PA positive human serum) was used 
to assess accuracy.  This was completed by testing whether there was a significant 
difference between the measured ELISA and the expected values based on the estimated 
AIG titer and the known titer of the positive serum.  This was performed separately for 
each serum type.  The coefficient of variation (%CV) was calculated for each dilution 
and serum type to detect any discrepancies in pipetting precision. 
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RESULTS  
Antibody Purification 
In order to reduce the volume of material administered to the rabbits used for this 
study the human plasma was column purified.  The purification process removed any 
anti-coagulants used during the plasma collection process that might interfere with the 
current study. 
Naive IgG was purified from BMI504 (a large pool of naïve human plasma, 
pooled at BMI and obtained from Interstate Blood Bank) by Covance Research Products 
(CRP) using Protein G sepharose affinity chromatography according to CRP SOPs.  The 
purified IgG was confirmed to be sterile and have acceptably low endotoxin levels 
(Cambrex, Walkersville, MD), and the total protein content (primarily IgG) was 
estimated to be 5.4 mg/ml by A280 spectrophotometric readings.  BMI received 31 sealed 
glass vials, from CRP, containing 100 ml each of purified naïve human IgG.   
Upon receipt, the product was determined to be intact and stored at approximately 
-20 °C.  Later inspection revealed that a majority of vials stored at -20 °C freezer had 
developed cracks.  The investigation identified that the breakage was due to the 
overfilling of the vials.  The broken vials were thawed in sterile 5 L vessels at room 
temperature, and the retained IgG material was sterile-filtered and aliquoted into 100 ml 
bottles containing 50 ml each and stored at 2-8 °C.    
Subsequently, 18 ml from bottles #5, #42, and #60 were removed and sub-
aliquoted into 0.5 ml and 1.0 ml aliquots for additional characterization assays.  Several 
0.5 ml aliquots were sent to CRP for testing of sterility and endotoxin levels, which were 
determined to be acceptable.  The results from the sterility, endotoxin, and total protein 
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concentration were provided in the certificate of analysis provided by CRP, summarized 
in Table 6.  The results obtained by CRP for the determination of total protein were 
varied.  The results obtained via BCA were reported as the most reliable according to 
CRP.  The total IgG protein concentration used for the study was obtained by averaging 
the results from the BCA, IgG ELISA, and A280 spectrophotometric tests. 
 
Table 6.  Purified Naïve Human IgG Product Specifications: BMI-504-PurIgG   
 
Description of 
Analysis/Test 
Specification 
(Units) 
Results  
(Units) Method 
Endotoxin <1.0 EU <0.07 EU LAL Testing (Cambrex) 
Sterility Pass Pass Final Container (Taconic) 
Protein IgG 
Concentration by 
ELISA 
>5.0 mg/ml 8.78 mg/ml1 Covance SOP 46122 
BCA Concentration >5.0mg/ml 5.97 mg/ml1 Covance SOP 46121 
PAGE-SDS Gel Qualitative Heavy and light chains visible 
Covance SOP 
46077 
Concentration by 
A280nm 
>5.0 mg/ml 5.47 mg/ml1 Covance SOP 46069 
1 Value is an average of three samples (beginning, middle, and end via ls). 
 
The control material, once confirmed sterile with acceptable endotoxin levels, was 
characterized by anti-PA ELISA (BMI) to confirm the negativity.  These results are 
summarized in Table 7. 
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Table 7.  Anti-PA ELISA-Specific Characterization Information for Purified Naïve 
Human: BMI-504-PurIgG. 
 
General Information 
Lot Number BMI504-PurIgG 
IgG Filter and Re-Pool Date November 22, 2005 
Expiration at 2 – 8°C November 22, 20061 
Specific Information for Unknown Test Sample Application (n = 4) 
Average anti-PA IgG Concentration 0.000 µg/ml 
Standard Deviation 0.000 µg/ml 
%CV 0.00% 
Acceptance Range (average conc. ±3 Std. Dev.) N/A 
Dilution for use as a Test Sample (Recommended) 1:50 
1 This date is an approximation without supporting stability studies. 
 
The AIG test material was purified from BMI505 (a pool of human plasma from 
AVA vaccinated volunteers received from Cangene Corporation) by CRP using Protein 
G sepharose affinity chromatography. The first round of purification yielded purified 
total  IgG (containing anti-PA IgG) and was assigned the lot number BMI505-purIgG.   
BMI505-purIgG was determined to have an average endotoxin level of 2.62 EU/ ml 
(Cambrex). These levels exceeded the maximum levels required for use in animal studies 
(1.0 EU/ ml) therefore, BMI505-purIgG required detoxification.   
BMI505-purIgG material was pooled and processed by CRP using a “Detoxi-Gel” 
endotoxin removal column (Pierce, Rockford, IL).  The final product resulting from this 
detoxification process was assigned the lot number BMI505-purIgG-rework.  The 
detoxification was not successful, as BMI505-purIgG-rework was determined to have an 
average endotoxin level of 2.09 EU/ ml (Cambrex).  BMI505-purIgG-rework was pooled 
and processed again by CRP using a different type of detoxification matrix referred to as 
the “EndoTrap” column (Cambrex). The matrix utilizes a ligand technology derived from 
a bacteriophage to bind the endotoxin.  
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The resulting product, , assigned the lot number BMI506-purIgG, was determined 
to have an average endotoxin content of 0.076 EU/ ml (Cambrex), and total protein 
content of approximately 4.8 mg/ml as measured by A280 spectrophotometric readings 
(CRP).  The endotoxin levels were acceptably low and the total IgG concentration 
acceptably high for use as the test material.  However, this product failed Taconic 
(Hudson, NY) sterility tests and filter sterilization was necessary.  The final version of 
this product, lot number of Cov-060320-purIgG was determined to be sterile (Taconic).  
The results from the sterility, endotoxin, and total protein concentration were provided in 
the certificate of analysis provided by CRP, summarized in Table 8.  Again the results 
obtained by CRP for the determination of total protein were varied.  The total IgG protein 
concentration used for the study was obtained by averaging the results from the BCA, 
IgG ELISA, and A280 spectrophotometric tests. 
 
Table 8.  Purified AIG Product Specifications: Cov-060320-purIgG    
 
Description of 
Analysis/Test 
Specification 
(Units) 
Results  
(Units) Method 
Endotoxin <1.0 EU <0.62 EU LAL Testing (Cambrex) 
Sterility Pass Pass Final Container (Taconic) 
Protein IgG 
Concentration by 
ELISA 
>5.0 mg/ml 9.21 mg/ml1 Covance SOP 46122 
BCA Concentration >5.0mg/ml 6.36 mg/ml1 Covance SOP 46121 
PAGE-SDS Gel Qualitative Heavy and light chains visible 
Covance SOP 
46077 
Concentration by 
A280nm 
>5.0 mg/ml 5.88 mg/ml1 Covance SOP 46069 
1 Value is an average of three samples (beginning, middle, and end vials). 
 
 27 
Cov-060320-purIgG was characterized by ELISA for anti-PA IgG concentration.  
The results used to determine the unknown anti-PA concentration for Cov-060320-
purIgG were obtained by assaying the product 24 different times by a single test operator 
(8 independent iterations each from retention vials #1, #26, and #51).  The anti-PA 
ELISA-specific characterization information is detailed in Table 9.   
 
Table 9.  Anti-PA ELISA-Specific Characterization Information for AIG: Cov-
060320-PurIgG. 
 
General Information 
Lot Number Cov-060320-purIgG 
Receipt Date April 6, 2006 
Expiration at 2 – 8°C April 6, 20071 
Specific Information for Unknown Test Sample Application (n = 24) 
Average anti-PA IgG Concentration 688 µg/ml 
Standard Deviation 23.7 µg/ml 
%CV 3.44% 
Acceptance Range (average conc. ±3 Std. Dev.) N/A 
Dilution for use as a Test Sample (Recommended) 1:200 
1 This date is an approximation without supporting stability studies. 
 
 
Passive Antibody Administration 
 Animals in Groups 1-4 were administered IP treatments as described in Table 10.  
All treatments were given using a 16 gauge 1 in. needle attached to a 10 in. catheter.  
Prior to dosing, the placement of the needle was confirmed in the peritoneal cavity via 
aspiration with a 3 ml syringe.  All doses were rounded to the nearest 0.1 ml.  The dosage 
volumes of AIG ranged from 16.5 - 78.1 ml.  The dose volumes of naïve IgG contained 
the same total protein dose as the animals in Group 3 (207.8 mg/kg), and ranged from 
72.8 – 83.6 ml (Table 10).  All doses were followed by a 3.0 ml flush of 0.9% 
physiological saline.  
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Table 10.  Animal Treatment Volumes and Total Protein Dose by Group 
 Animal I.D. Group Sex 
Animal 
Wt 
(kg)  
5/8/06 
Treatment Dosage 
(anti-PA mg/kg) 
Treatmen
t Volume 
(ml) 
Total 
Protein 
(mg/kg) 
2077 1 M 2.2881 5 16.6 52.0 
2088 1 M 2.3035 5 16.7 52.0 
2090 1 M 2.3021 5 16.7 52.0 
2096 1 M 2.2756 5 16.5 52.0 
2217 1 F 2.4871 5 18.1 52.0 
2212 1 F 2.5434 5 18.5 52.0 
2206 1 F 2.4002 5 17.4 52.0 
2220 1 F 2.6891 5 19.5 52.0 
2095 2 M 2.5613 10 37.2 103.9 
2086 2 M 2.4791 10 36.0 103.9 
2080 2 M 2.3946 10 34.8 103.9 
2081 2 M 2.4058 10 35.0 103.9 
2214 2 F 2.6819 10 39.0 103.9 
2213 2 F 2.7203 10 39.5 103.9 
2221 2 F 2.5462 10 37.0 103.9 
2203 2 F 2.3746 10 34.5 103.9 
2084 3 M 2.4057 20 69.9 207.8 
2085 3 M 2.5042 20 72.8 207.8 
2076 3 M 2.3729 20 69.0 207.8 
2091 3 M 2.4106 20 70.1 207.8 
2216 3 F 2.4785 20 72.0 207.8 
2218 3 F 2.6143 20 76.0 207.8 
2207 3 F 2.6269 20 76.4 207.8 
A
IG
 
2209 3 F 2.6857 20 78.1 207.8 
2078 4 M 2.5032 Group 3 total IgG 77.2 207.8 
2083 4 M 2.4783 Group 3 total IgG 76.4 207.8 
2082 4 M 2.3596 Group 3 total IgG 72.8 207.8 
2092 4 M 2.5073 Group 3 total IgG 77.3 207.8 
2205 4 F 2.5151 Group 3 total IgG 77.6 207.8 
2208 4 F 2.4923 Group 3 total IgG 76.9 207.8 
2201 4 F 2.5321 Group 3 total IgG 78.1 207.8 
N
ai
ve
 I
gG
 
2210 4 F 2.7116 Group 3 total IgG 83.6 207.8 
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Clinical Observations 
 To ensure that the passively administered material was non-toxic to the rabbits, all 
animals in Groups 1-4 were observed continuously for at least 1 h post IP-treatment.  
There were no apparent signs of toxicity observed during this period.  All animals in 
Groups 1-4 remained normal during the twice daily observations over the 14-day period 
after treatment (Table 11).  A single animal in Group 2 exhibited brief periods of 
inappetence on Study Days 7, 9, and 12 post-treatment.  It can be speculated that these 
periods of inappetence were related to times when the animal was tranquilized for blood 
collections. 
 
 
Table 11.  Summary Table of Observed Post-Treatment Clinical Observations 
 
Number of animals in each group that demonstrated the clinical  
observation at least once during the observation period Clinical  
Observation Group 1 
(n=8) 
Group 2 
(n=8) 
Group 3 
(n=8) 
Group 4 
(n=8) 
Group 5 
(n=8) 
Normal 8 8 8 8 8 
Not eating 0 1 0 0 0 
 
 
B. anthracis Aerosol Challenges 
 Aerosol challenges were conducted as described in BMI SOP Numbers 
MREF.XIII-001 and MREF.XIII-011. A Collison 3-jet nebulizer (BGI Inc., Waltham, 
MA) was used to aerosolize the biological agent, B. anthracis (Ames strain, BMI), for the 
challenge.  Filtered “house” air was provided to supply a continuous and regulated air 
source to the Collison nebulizer and for additional dilution air.  As the aerosolized B. 
anthracis exited the Collison, additional humidified air was introduced through a bubbler 
 30 
into the aerosol stream to dilute the aerosol and regulate humidity in the system during 
each exposure.  Nebulizer bypass air and humidified dilution air was provided to the 
animal during the pre exposure periods of testing.  At the initiation of each animal 
challenge, the bypass airflow was turned off and the air redirected to the Collison 
nebulizer for aerosol generation.  
Supply air pressure for system operation was regulated and maintained at 
approximately 30 psi for all exposure challenges.  The Collison nebulizer bypass airflow 
was regulated and controlled at approximately 7.4 L/min and the humidified dilution air 
at approximately 8.7 L/min using a 0 to 20 L/ min mass flow controller (Sierra 
Instruments, Monterey, CA).  Relative Humidity levels in the exposure system were 
maintained in the range of 52% to 87 % during exposures, and were monitored using a 
temperature and humidity monitor model 605-H1 (SKC, Inc., Fullerton, CA).  The 
nebulizer flow rate was maintained at approximately 7.5 L/min by supplying a 
continuous and regulated air supply to the nebulizer in the range of 27 to 29 psi.   
The aerosol sampling system consisted of a model 7541 impinger (Ace Glass, 
Inc., Vineland, NJ), and an Aerodynamic Particle Sizer Spectrometer model 3321 (TSI, 
Inc., St Paul, MN).  A flow validated impinger filled with approximately 20 ml of sterile 
water (Sigma) was used to collect a representative fraction of the challenge aerosol from 
the exposure system.  An impinger sample was collected during aerosol challenge to 
determine the respirable colony forming unit (cfu) concentration delivered to the animal.  
A single 30 s sample was pulled from the system during each animal exposure challenge 
at a flow rate of 0.5 L/min.  These samples were plated on trypticase soy agar (TSA) to 
obtain the approximate LD50s administered to each animal (Table 12).  Flow rate through 
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the impinger was maintained at approximately 6 L/ min by maintaining a negative 
pressure of 18 inches of Hg using a 1/5 hp vacuum pump (Gast Manufacturing, Benton 
Harbor, MI).  An Aerodynamic Particle Sizer Spectrometer (APS) was used to measure 
the size distribution of the B. anthracis aerosol.  .   
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Table 12.  Aerosol LD50 Equivalents and Time to Death by Dose Group 
 
Animal ID Group 
Dosing  
Material 
anti-PA Dose  
(mg/kg) 
Aerosol LD50 
Equivalents 
Days  
Till Death 
2091 3 AVA IgG 20 225 2 
2085 3 AVA IgG 20 349 3 
2216 3 AVA IgG 20 229 3 
2207 3 AVA IgG 20 190 3 
2076 3 AVA IgG 20 400 4 
2218 3 AVA IgG 20 306 4 
2084 3 AVA IgG 20 183 4 
2209 3 AVA IgG 20 188 8 
2208 4 Naïve IgG NA 377 3 
2205 4 Naïve IgG NA 268 3 
2078 4 Naïve IgG NA 220 3 
2082 4 Naïve IgG NA 339 4 
2201 4 Naïve IgG NA 295 4 
2210 4 Naïve IgG NA 220 4 
2092 4 Naïve IgG NA 191 4 
2083 4 Naïve IgG NA 333 5 
2219 5 None NA 442 3 
2093 5 None NA 345 3 
2094 5 None NA 323 3 
2097 5 None NA 297 3 
2202 5 None NA 248 3 
2087 5 None NA 228 3 
2215 5 None NA 142 4 
2204 5 None NA 179 5 
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Post Challenge Clinical Observations and Mortality 
Adverse clinical observations on rabbits from the time of the anthrax challenge to 
the end of the study included:  inappetence, soft stool, no stool, wheezing, sneezing, 
rough hair coat, lethargy, loss of coordination, abnormal posture/gait, milky lacrimations, 
moribundity, seizure, and death.   Many rabbits showed signs of clinical illness 
(inappetence, lethargy and/or moribundity) leading up to their time of death or 
euthanasia.  Inappetence was a common observation during the first few days following 
challenge in all groups. This inappetence could be due to the anthrax infection and/or the 
stress of daily activities (e.g. blood draws) in the animal rooms.  Although a majority of 
the animals that died exhibited inappetance just prior to death, a period of inappetence 
was not always predictive of a fatal outcome.  Other symptoms of anthrax, such as 
lethargy/recumbency and respiratory distress, were less commonly observed and most 
likely due to the rapid progression to death seen in rabbits.  The post-challenge 
observations are detailed in Table 13.  
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Table 13.  Post Challenge Clinical Observations 
Study Day 15 16 17 18 19 20 21 22 
Animal ID Group AM PM AM PM AM PM AM PM AM PM AM PM AM PM AM PM 
2084 3 N N N N NE N D          
2085 3 N N N N NE D           
2076 3 N N N N NE L D          
2091 3 N N L, U, M, E              
2216 3 N N N N NE, S, E            
2218 3 N N NE,L NE NE NE,L NE,L, D          
2207 3 N N N N NE D           
2209 3 N N N N N N N NE,L NE NE NE NE,NS NE NE,NS NE,L,D  
2078 4 N N N NE, L D            
2083 4 N N N N NE SS N, SN NE, RD D        
2082 4 N N N N NE NE, L D          
2092 4 N N SS N NE, L SS, NE, L, RD D          
2205 4 N N N N NE D           
2208 4 N N L NE, L D            
2201 4 N N NE NE NE N D          
2210 4 N N NE NE NE, W NE, RD D          
2097 5 N N N NE D            
2087 5 N N N 
L, NE, 
ML, RHC, 
AP 
D            
2094 5 N N N N D            
2093 5 N N N NE D            
2202 5 N N NE NE D            
2219 5 N N NE NE NE, L, U, AP, D            
2215 5 N N NE, L NE,L NE, L NE, NS, L           
2204 5 N N N N N N NE NE,L NE,L,D        
AP=Abnormal Posture     D=Dead E=Euthanized  L=lethargic  M=Moribund  ML=Milky Lacrimations  N=Normal      NE=Not Eating        NS=No Stool 
RD=Respiratory Distress       RHC= Rough Hair Coat S=Seizure SS=Soft Stool SN= Sneezing U=Uncoordinated        W=Wheezing  
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Figure 2 shows the cumulative percent of totals dead by days post-challenge.  
Groups 4 and 5 reached 100% mortality by Study Days 4 and 5 post-challenge, 
respectively.  Group 3 reached 100% mortality by 8 days post-challenge.    
 
Figure 2.  Percent of Total Dead versus Days Post Challenge 
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Table 14 shows the survivability and time to death statistics for Groups 3-5.  The 
average to time death and standard deviations are included for each group. 
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Table 14.  Survivability and Time to Death for Challenge Groups 
Animal 
ID Sex Group 
Ames 
LD 50 
Challenge 
Date and 
Time 
Survival 
Status 
Date and Time 
of Death 
Days to 
Death 
        
2076 F 3 400 5/23/06 13:29 Died 5/27/06 6:20 3.7 
2084 F 3 183 5/23/06 13:15 Died 5/27/06 6:20 3.7 
2085 M 3 349 5/23/06 12:08 Died 5/26/06 13:50 3.1 
2091 M 3 225 5/23/06 10:41 Died 5/25/06 9:27 1.9 
2207 F 3 190 5/23/06 11:44 Died 5/26/06 13:50 3.1 
2209 F 3 188 5/23/06 10:54 Died 5/31/06 8:15 7.9 
2216 M 3 229 5/23/06 11:34 Died 5/26/06 7:30 2.8 
2218 M 3 306 5/23/06 11:56 Died 5/27/06 8:20 3.8 
    Survival  0/8 Average 3.8 
      Stnd Dev 1.8 
2078 F 4 220 5/23/06 11:08 Died 5/26/06 6:50 2.8 
2082 F 4 339 5/23/06 12:55 Died 5/27/06 6:20 3.7 
2083 M 4 333 5/23/06 13:40 Died 5/28/06 6:32 4.7 
2092 M 4 191 5/23/06 9:45 Died 5/27/06 6:20 3.9 
2201 F 4 295 5/23/06 12:31 Died 5/27/06 6:20 3.7 
2205 F 4 268 5/23/06 10:12 Died 5/26/06 13:50 3.2 
2208 M 4 377 5/23/06 12:20 Died 5/26/06 6:50 2.8 
2210 M 4 220 5/23/06 9:56 Died 5/27/06 6:20 3.8 
    Survival  0/8 Average 3.6 
      Stnd Dev 0.6 
2087 F 5 228 5/23/06 9:10 Died 5/26/06 6:50 2.9 
2093 F 5 345 5/23/06 13:53 Died 5/26/06 6:50 2.7 
2094 M 5 323 5/23/06 13:09 Died 5/26/06 6:50 2.7 
2097 M 5 297 5/23/06 12:44 Died 5/26/06 6:50 2.8 
2202 F 5 248 5/23/06 10:26 Died 5/26/06 6:50 2.8 
2204 F 5 179 5/23/06 11:20 Died 5/28/06 8:32 4.9 
2215 M 5 142 5/23/06 9:32 Died 5/27/06 6:20 3.9 
2219 M 5 442 5/23/06 9:23 Died 5/26/06 7:40 2.9 
     Survival  0/8 Average 3.2 
            Stnd Dev 0.8 
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ELISA Pilot Study 1  
This pilot study was conducted to determine the ability of the human IgG ELISA 
to recover the purified AIG (Cov-060320-purIgG) in naïve human serum (093K0475), 
naïve rabbit serum (BMI012), positive rabbit serum (BMI023), and PBS for a series of 
expected concentrations.  It was unclear how accurately the human anti-PA ELISA would 
detect the AIG material from positive rabbit serum collected for this project.  This pilot 
study compared the assay’s recovery rate from the four different test diluents.     
Table 15 contains the baseline ELISA results for the individual materials used in 
this pilot study.  The ELISA test results are presented in Table 16 and Figure 4.  The 
actual ELISA values listed represent the mean from the 3 independent results.   The 
expected concentrations are based upon the AIG material having a concentration of 705 
µg/ml.   
 
Table 15.  ELISA Results on Individual Test Materials 
Test Material Mean Anti-PA ELISA Concentration (µg/ml)1 
AIG 705 
Diluents  
Naïve Rabbit 0 
anti-PA IgG Positive Rabbit 27 
Naïve Human 0 
PBS 0 
      1 Results are from anti-PA ELISA using anti-human conjugate  
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Table 16. ELISA Pilot Study 1 Results for the Test Samples 
   Mean Anti-PA ELISA Concentration (µg/ml) 
Group Diluent 
AIG1 
Dilution 
Factor 
Actual Expected5 % Recovery 
1 10 43 71 61 % 
2 25 23 28 82 % 
3 50 14 14 100 % 
4 
Naïve Rabbit2 
100 5.4 7 77 % 
5 10 103 98 105 % 
6 25 48 55 87 % 
7 50 37 41 90 % 
8 
Anti-PA IgG 
Positive Rabbit3 
100 33 34 97 % 
9 10 55 71 77 % 
10 25 20 28 71 % 
11 50 10 14 71 % 
12 
Naïve Human4 
100 4.9 7 70 % 
13 10 50 71 70 % 
14 25 18 28 64 % 
15 50 9.0 14 64 % 
16 
PBS 
(control) 
100 4.4 7 63 % 
1 AIG is the test material (Lot Cov-060320-purIgG)  
2 Lot No. BMI012  
3 Lot No. BMI023 
4 Lot No. 093K0475  
5 Expected values is based upon the AIG mean anti-PA ELISA concentration of 705 µg/ml 
 
 
Figure 3 clearly shows that the ELISA assay detects both the purified human AIG 
and the rabbit IgG from the known positive rabbit serum (BMI023).  The results from the 
assays show a slight decrease in recovery from the expected values.   However, this is not 
unlikely as the test material AIG has not been as extensively characterized as the positive 
control serum BMI 023. 
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Figure 3.  ELISA Pilot Study 1 Results with Lines for Expected Concentration. 
 
 
 
Figure 4 shows the ELISA data plotted against the expected titers.  The expected 
titers were calculated from the dilutions used and the estimated titers of the purified AIG 
test material and the known positive rabbit serum (BMI023).  The solid lines are 
regression lines for each diluent and the dotted line represents the 45 degree line. 
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Figure 4.  ELISA Pilot Study 1 Values Plotted Versus Expected Concentrations.   
 
 
 
Table 17 contains the slope estimates from the analysis of covariance models 
fitted to the logarithms of the ELISA data.  The models included a continuous covariate 
for the logarithm of the expected titer, a factor for diluent and the interaction.  The table 
also contains the p-value for testing whether the slope estimate was significantly different 
from one.  To maintain an overall p value at the 0.05 level across the four diluents, p-
values were considered significant if they were less than the Bonferroni adjusted level of 
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0.0125 (if p=0.05/4 (4 represents the number of different diluents tested)).  No slopes 
were significantly different from one.  Thus, the hypotheses of dilutional linearity for the 
ELISA assays were not rejected for any of the diluents.   The intercepts from the ELISA 
model for the naïve human (p-value=0.0023) and PBS (p-value<0.0001) diluents were 
significantly less than zero.  This indicates a slight under-recovery for these diluents.   
 
Table 17.  Slope Estimates from ELISA Models with P-values for Testing If Slope is 
Significantly Different From One. 
 
ELISA 
Diluent 
Slope Estimate P-value* 
Naïve Human 1.05 0.3018 
Naïve Rabbit 0.88 0.0139 
PBS 1.06 0.1756 
Positive Rabbit 1.14 0.1709 
     * No slopes significant at the Bonferroni adjusted 0.0125 (=0.05/4) level. 
 
Figure 5 shows the coefficient of variation (CV) from the ELISA data for each 
diluent and dilution.  The variability in the data appears to be greater for the 1:100 
dilutions which is not unexpected as these values were near (and sometimes less than) the 
ELISA Limit of Quantification (LOQ) of 2.5 µg/ml.  CVs for the other dilutions were 
less than 20 percent.  These plots provide evidence that the different diluents utilized in 
this pilot study do not adversely affect the precision of the human IgG ELISA assay.  The 
ELISA results confirm that there were no statistically significant differences for AIG 
between any of the naïve diluents and the results for positive rabbit serum were slightly 
elevated when compared to the naïve diluents.   
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Figure 5.  Coefficients of Variation for Each Diluent and Dilution for ELISA. 
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Pilot Study 2 Results  
 The under recovery of the positive AIG from the negative diluents was a concern 
since the majority of the samples used in determi ning the half-life of the AIG material 
were collected before the rabbit’s immune response would be detectable (less than 7 
days).  This pilot study would determine any statistical significant difference in the 
human IgG ELISA’s ability to recover positive test materials (AIG, the AVA source 
plasma, and a known positive human serum) from naïve diluents (naïve human serum, 
naïve rabbit serum, and PBS) at a dilution series of expected concentrations.   
The test results are presented in Tables 18-20 and Figures 6-8.  All actual values 
in the tables are the mean result of the three test samples results, while the figures plot the 
individual results.   
 
  
Table 18.  ELISA Pilot Study 2 Results for AIG in Each Diluent 
 
 Anti-PA ELISA Concentration (µg/ml) 
Diluent Dilution Factor Actual Expected
1 % Recovery 
10 60 69 88% 
25 23 28 82% 
50 11 14 77% 
Naïve Rabbit 
100 5.7 6.9 83% 
10 59 69 86% 
25 26 28 94% 
50 13 14 95% 
Naïve Human 
100 5.9 6.9 85% 
10 57 69 83% 
25 25 28 91% 
50 11 14 81% 
PBS 
(control) 
100 4.6 6.9 68% 
1 Expected ELISA values are based on AIG having an anti-PA level of 688 µg/ml. 
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Table 19.  ELISA Pilot Study 2 Results for AVA Plasma in Each Diluent 
  
 Anti-PA ELISA Concentration (µg/ml) 
Diluent Dilution Factor Actual Expected
1 % Recovery 
10 69 90 77% 
25 24 36 67% 
50 15 18 83% 
Naïve Rabbit 
100 7.1 9.0 79% 
10 78 90 87% 
25 25 36 69% 
50 15 18 83% 
Naïve Human 
100 7.5 9.0 83% 
10 68 90 76% 
25 25 36 69% 
50 12 18 67% 
PBS 
(control) 
100 6.3 9.0 70% 
1 Expected ELISA values are based on AVA Plasma having an anti-PA level of 901 µg/ml. 
 
Table 20.  ELISA Pilot Study 2 Results for Anti-PA IgG positive Human Serum in   
Each Diluent 
 
 Anti-PA ELISA Concentration (µg/ml) 
Diluent Dilution Factor Actual Expected
1 % Recovery 
10 10.5 10.9 96% 
25 4.3 4.4 98% 
50 2.6 2.2 118% 
Naïve Rabbit 
100 1.0 1.1 92% 
10 11.0 10.9 101% 
25 4.6 4.4 105% 
50 3.0 2.2 136% 
Naïve Human 
100 1.7 1.1 160% 
10 9.5 10.9 87% 
25 3.7 4.4 84% 
50 1.7 2.2 80% 
PBS 
(control) 
100 0.9 1.1 82% 
1 Expected ELISA values are based on anti-PA IgG positive Human Serum having an anti-PA level of 
109 µg/ml. 
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Figures 6-8 clearly show that the ELISA assay does detect the positive materials 
(AIG, AVA Plasma, and positive human serum) in all three of the diluents.  Plots of the 
ELISA data show that most of the results are within 20-30 percent of the expected value 
for all dilutions and spiking materials.  The AVA plasma had the lowest recovery in all 
diluents, yet the recovery was relatively consistent across diluents.  The recovery of the 
positive materials from PBS was lower than in the naïve rabbit and naïve human serum.  
This is consistent with the lower recoveries observed in the initial pilot study. 
Figure 6.  ELISA Pilot Study 2 Results for AIG with Lines for Expected 
Concentration. 
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Figure 7. ELISA Pilot Study 2 Results for AVA Plasma with Lines for Expected 
Concentration. 
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Figure 8.  ELISA Pilot Study 2 Results for Anti-PA IgG positive Human Serum with 
Lines for Expected Concentration. 
 
 
 
 
Figures 9-11 show the ELISA data plotted against the expected titers.  The 
expected titers were based on the dilutions used and the estimated titers of the positive 
serum (AIG, AVA Plasma and positive human serum).  The solid lines in the plots are the 
regression lines fitted to the data and the dotted line in each plot is the 45 degree line.  
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Figure 9.  ELISA Pilot Study 2 Values for AIG Plotted Versus Expected 
Concentrations.   
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Figure 10.  ELISA Pilot Study 2 Values for AVA Plasma Plotted Versus Expected 
Concentrations.   
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Figure 11.  ELISA Pilot Study 2 Values for Anti-PA IgG Positive Human Serum 
Plotted Versus Expected Concentrations. 
   
 
 
 
 Table 21 contains the slope and intercept estimates from the analysis of 
covariance models fitted to the logarithms of the ELISA data for each spiking material.  
The models included a continuous covariate for the logarithm of the expected titer, a 
factor for diluent and the interaction.  The table also contains the p-values for testing 
whether the slope estimate was significantly different from one and whether the intercept 
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estimate was significantly different from zero for each diluent.  To maintain an overall 
0.05 level across the three diluents, p-values were considered significant if they were less 
than the Bonferroni adjusted level of 0.0167 (0.05/ 3).     
The slopes from the ELISA models were significantly different from one and 
intercepts were significantly different from zero for AIG diluted into PBS and anti-PA 
IgG positive human serum diluted into naïve human serum.  In addition, the intercepts 
from the ELISA model using anti-PA IgG positive human serum diluted in naïve human 
serum (p-value<0.0001) was significantly greater than zero and diluted in PBS (p-
value<0.0001) was significantly less than zero.  These results may be due to values that 
are less than the LOQ for the assay.  For AVA Plasma diluted into PBS the intercept (p-
value<0.0001) was significantly less than zero.  The intercept was significantly less than 
zero for AIG diluted into naïve rabbit serum (p-value=0.0018) and PBS (p-
value<0.0001).  It appears that these results are indicative of a slight under-recovery in 
PBS and in naïve rabbit serum for AIG.   
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Table 21.  Slope and Intercept Estimates from ELISA Models With P-values for 
Testing if Slope was Significantly Different from One and Intercept was 
Significantly Different from Zero 
Slope Intercept Positive Serum Diluent 
Estimate P-value Estimate P-value 
Naïve Human 1.00 0.9440 -0.04 0.2474 
Naïve Rabbit 1.03 0.2306 -0.13 0.0018* AIG 
PBS 1.09 0.0028* -0.21 <.0001* 
Naïve Human 1.00 0.9620 -0.09 0.0470 
Naïve Rabbit 0.96 0.1525 -0.05 0.2380 AVA Plasma 
PBS 1.04 0.1828 -0.21 <.0001* 
Naïve Human 0.79 <.0001* 0.20 <.0001* 
Naïve Rabbit 0.99 0.7494 0.01 0.7044 
Anti-PA IgG 
positive Human 
Serum 
PBS 1.03 0.2913 -0.09 <.0001* 
* Significant at the Bonferroni adjusted 0.0167 (=0.05/3) level. 
 
 
Figures 12-14 show the coefficient of variation (CV) from the ELISA data for 
each positive serum, diluent and dilution.  For the ELISA data all CVs were less than 20 
percent.  These plots provide evidence that the different diluents do not adversely affect 
the precision of the ELISA assay. 
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Figure 12.  Coefficients of Variation for AIG ELISA Values from Each Diluent and 
Dilution. 
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Figure 13. Coefficients of Variation for AVA Plasma ELISA Values from Each 
Diluent and Dilution. 
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Figure 14.  Coefficients of Variation for Anti-PA IgG Positive Human Serum ELISA 
Values from Each Diluent and Dilution. 
 
 
The ELISA data for the second pilot study is less consistent than data from the 
first pilot study, but overall there does not appear to be a clear issue caused by spiking 
AIG, AVA plasma, or positive human serum into naïve rabbit serum.  Spiking serum into 
PBS lead to lower than expected results indicating an under recovery.  Based on the 
results of these pilot studies spiking positive material into PBS versus serum (human or 
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rabbit), one would expect the serum-spike material recovery to be higher.  This 
conclusion is supported by the data in this pilot study.   
There appeared to be recovery issues with spiking AVR801 (positive human 
serum) in any of the negative matrices at 1:50 and 1:100. This dilution of AVR801 (109.4 
µg/ml) resulted in an expected concentration of 2.2 and 1.1 µg/ml, (below the ELISA’s 
LOQ of 2.5 µg/ml).  The other recoveries of AVR801 at lower dilutions are excellent.  
The recoveries of the AIG and AVA plasma are slightly lower than expected. However, 
they have not had the same level of characterization in the anti-PA ELISA to determine 
their expected concentrations.  It is not unexpected that these recoveries are lower.  The 
recoveries are consistent across matrices suggesting that any diluents’ effects are 
negligible, however it appears that PBS consistently produced a lower recovery than 
human or rabbit serum. 
 
Anti-PA ELISA and KINETIC RESULTS 
 Table 22 shows the median ELISA anti-PA IgG concentration (µg/ml) for all 
groups at the listed time points.  All data points below the assay’s LOQ are listed as < 
2.5.  Group 4 (Naïve IgG) was undetectable at all time points as expected.  Groups 1-3 
showed an increase in anti-PA concentration for most animals at the 1 h time point and an 
increase in anti-PA concentration for all treatment animals at 24 h.  This change in anti-
PA concentration indicated a proper placement of the catheter during antibody 
administration.  The 24 h time point also represents the mean peak for Groups 1-3.  
 The animal ELISA kinetic data shows that ample protection against a lethal B. 
anthracis should be present at 24 h post treatment for Groups 2 and 3 (10 and 20 AIG 
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mg/kg, respectively).  This is based on historical data showing that a titer of 60-65 µg/ml  
will provide nearly 95% protection against a lethal aerosol challenge in NZW Rabbits. It 
is also probable that some protection will be afforded at 7 days post treatment for Group 
3 dose levels. 
 58 
Table 22.  Median ELISA anti-PA IgG Concentrations for all Samples 
 
 Sample Time (h post IP administration) 
 
-1 1 hr 
24 
hr 
48 
hr 
72 
hr 
96 
hr 
Day 
7 
Day 
10 
Day
13  
Day
16  
Day 
19 
Day 
22 
Day 
25 
Day 
28  
Animal  Median ELISA anti-PA IgG (µg/ml)1 
2077 <2.5 <2.5 41 43 38 29 27 21 12 9 6 5 3 <2.5 
2088 <2.5 <2.5 58 40 39 34 17 11 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 
2090 <2.5 5 79 57 46 35 16 4 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 
2096 <2.5 14 75 49 45 29 15 6 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 
2217 <2.5 <2.5 48 47 41 39 18 19 6 4 <2.5  <2.5 <2.5 <2.5 
2212 <2.5 <2.5 30 43 41 35 22 9 <2.5 <2.5 <2.5  <2.5 <2.5 <2.5 
2206 <2.5 7 58 58 45 31 15 <2.5 <2.5 <2.5 <2.5  <2.5 <2.5 <2.5 
G
ro
up
 1
 (5
 m
g/
kg
 a
nt
i-
PA
 
Ig
G
) 
2220 <2.5 <2.5 29 51 53 40 30 25 6 <2.5 <2.5  <2.5 <2.5 <2.5 
2095 <2.5 8 148 95 79 71 43 33 12 5 <2.5 <2.5 <2.5 <2.5 
2086 <2.5 4 134 98 111 57 53 32 10 <2.5 <2.5 <2.5 <2.5 <2.5 
2080 <2.5 <2.5 12 8 9 7 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 
2081 <2.5 4 9 90 103 66 55 35 10 <2.5 <2.5 <2.5 <2.5 <2.5 
2214 <2.5 55 207 128 113 100 78 53 25 15 10 6 <2.5 <2.5 
2213 <2.5 7 187 111 90 75 56 43 13 4 <2.5 <2.5 <2.5 <2.5 
2221 <2.5 18 168 104 81 76 48 29 13 6 <2.5 <2.5 <2.5 <2.5 
G
ro
up
 2
 (1
0 
m
g/
kg
 a
nt
i-
PA
 
Ig
G
) 
2203 <2.5 4 186 95 77 67 36 13 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 
2084  <2.5 13 272 236 173 154 111 65 34 5 DEAD 
2085  <2.5 18 402 182 144 132 105 81 42 9 DEAD 
2076  <2.5 9 410 211 155 178 94 45 3 0 DEAD 
2091 <2.5 7 444 186 143 133 67 19 <2.5 <2.5 DEAD 
2216  <2.5 23 553 241 193 151 90 62 5 <2.5 DEAD 
2218  <2.5 4 217 181 171 98 120 125 53 44 DEAD 
2207  <2.5 36 391 238 200 147 132 138 57 6 DEAD 
G
ro
up
 3
 (2
0 
m
g/
kg
 a
nt
i-
PA
 
Ig
G
) 
2209  <2.5 15 404 277 207 174 141 109 49 20 <2.5 181 DEAD 
2078  <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 DEAD 
2083  <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 DEAD 
2082 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 DEAD 
2092 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 DEAD 
2205 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 DEAD 
2208  <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 DEAD 
2201 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 DEAD 
G
ro
up
 4
 (C
on
tr
ol
) 
2210 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 <2.5 DEAD 
 
1 < 2.5 represents a value below the ELISA LOQ of 2.5 µg/ml.   
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Table 23 shows the means for groups 1-4 and the respective standard deviations. 
Table 23.  Means and Standard Deviations for all Dose Groups 
 
 
Day 
-1 1 hr 
24 
hr 
48 
hr 
72 
hr 
96 
hr 
Study 
Day  
7 
Study 
Day 
10 
Study 
Day 
13  
Study 
Day 
16  
Study 
Day 
19 
Study 
Day 
22 
Study 
Day 
25 
Study 
Day 
28 
Mean < LOQ 
9 52 49 44 34 20 14 8 7 6 5 3 < LOQ Group 
1 (5 
mg/kg 
AIG) 
S.D. 
< 
LOQ 5 19 6 5 4 6 8 4 4 < LOQ < LOQ < LOQ < LOQ 
Mean < LOQ 
14 131 91 76 65 53 34 14 7 10 6 < LOQ < LOQ Group 
2 (10 
mg/kg 
AIG) 
S.D. 
< 
LOQ 19 78 36 30 26 13 12 6 5 < LOQ < LOQ < LOQ < LOQ 
Mean < LOQ 
16 386 219 170 146 107 81 35 14 < LOQ 181 < LOQ < LOQ Group 
3 (20 
mg/kg 
AIG) 
S.D. 
< 
LOQ 10 103 35 29 25 24 41 22 16 < LOQ < LOQ < LOQ < LOQ 
Mean < LOQ 
< 
LOQ 
< 
LOQ 
< 
LOQ 
< 
LOQ 
< 
LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Group 
4 
(Naive) S.D. 
< 
LOQ 
< 
LOQ 
< 
LOQ 
< 
LOQ 
< 
LOQ 
< 
LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
 
Table 24 lists the Natural Log (Ln) [Median ELISA anti-PA IgG (µg/ml)] for 
Groups 1-3 at the respective time points for all positive response groups and the kinetic 
evaluation of these groups including slopes, R2, and half-life (t ½).  The kinetics 
evaluations represent Study Days 0-14 (prior to challenge).  The mean t ½ for groups 1-3 
is 4.267 days with a standard deviation of 0.06.  These results illustrate that t ½ is 
independent of dose for 1st order kinetics as expected. 
Figure 15 shows the mean values from Table 19 plotted versus time for all AIG 
dose groups.     
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Table 24.  Kinetic Determinations for AIG Dose Groups 
 
Ln [Median ELISA anti-PA IgG (µg/ml)] Kinetics Evaluation of results 
 
1  
hr 
24 
hr 
48 
hr 
72 
hr 
96 
hr 
Study 
Day  
7 
Study 
Day 
10 
Study 
Day 
13 
Slope R2 
t ½ 
1
  
(hr) 
t ½ 
1 
(d) 
Group 1 
(5 mg/kg 
AIG) 
2.1 4.0 3.9 3.8 3.5 3.0 2.6 2.1 -0.0067 0.994 104 4.3 
Group 2 
(10mg/kg 
AIG) 
2.7 4.9 4.5 4.3 4.2 4.0 3.5 2.6 -0.0068 0.952 103 4.3 
Group 3 
(20mg/kg 
AIG) 
2.8 6.0 5.4 5.1 5.0 4.7 4.4 3.5 -0.0069 0.935 100 4.2 
1  Half-life = Ln2 /Slope R2 
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Figure 15.  Mean anti-PA Concentrations Versus Time for all AIG Dose Groups 
 
 Passive Transfer Kinetics Results
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DISCUSSION   
 
The efficacy of a treatment, such as passive immunization, cannot be tested in 
humans due to ethical considerations.  New treatments are tested in at least one 
appropriate animal species prior to submission to the Food and Drug Administration 
(FDA).  The rabbit model was chosen for this project since lesions observed following an 
inhalation anthrax challenge are similar to those of inhalation anthrax found in humans 
and rhesus macques (Zaucha et al., 1998).  The rabbit model in this study consisted of an 
aerosol B. anthracis challenge with an average 272 LD50 (Ames strain).  The objectives 
of this study were to 1) evaluate the kinetics of passively transferred human 
immunoglobulin G (IgG) AIG via Anti-PA ELISA, to; 2) investigate the potential lethal  
toxicity,  of the passively administered test and control materials; and 3) determine the 
efficacy against a delayed lethal aerosol challenge of B. anthracis (Ames strain). 
All animals receiving IP treatments were observed continuously for one h post 
administration and twice daily for signs of toxicity.  All animals appeared normal during 
the one h post AIG or naïve IgG administration.  There were no significant changes in 
appearance, behavior, or responsiveness.  No clinical signs consistent with toxicity were 
observed during the 14 days post-treatment.  A single animal exhibited a brief decrease in 
appetite which correlates closely with the periodical sedation for blood draws. 
Adverse clinical observations post-challenge were consistent with a B. anthracis 
infection in the rabbit model.  The clinical symptoms observed for this study included: 
not eating, soft stool, no stool, wheezing, sneezing, abnormal posture or gait, lethargy, 
loss of coordination, milky lacrimations, morbundity, and seizure.  All animals were 
observed to be abnormal during the 24-h period proceeding death or euthanasia.  There 
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was no protection efficacy afforded by the passively transferred antibodies in the delayed 
exposure scenario used for this study.  All animals in Groups 3, 4, and 5 were found dead 
or euthanized by Study Day 8 post-challenge.  There was no statistically significant 
increase in time to death between groups.  The average time to death for Groups 3, 4, and 
5 were 3.8, 3.6, and 3.2 respectively as shown in Table 12 (pp. 37).  
Prior to testing the rabbit sera on this study (via anti-PA ELISA), two pilot studies 
were conducted to evaluate the assay’s ability to detect the human IgG in rabbit sera.  
Several well characterized BMI reagents were used for these pilot studies.  The first pilot 
study evaluated the recovery of the purified AIG material spiked into naïve rabbit serum, 
anti-PA IgG positive rabbit serum, naïve human serum, and PBS.  The calculations for 
percent recovery were performed using the expected and observed anti-PA concentration 
(µg/ml).  The results presented in Table 15 (pg 38) clearly show that the ELISA assay 
detects the purified AIG from the tested diluents.  The slight decreases observed in 
recovery were not unlikely due to the limited characterization of the AIG test material.  
PBS was the least reliable of the diluents. 
   The CV from the ELISA data shows an increase in variability for the 1:100 
dilutions.  These values were near and sometimes less than the assay’s LOQ which 
explains the increase in variability.  The ELISA results confirm that there were no 
statistically significant differences for AIG between any of the naïve diluents and the 
results for AIG in positive rabbit serum were slightly elevated.  Additionally, the data 
demonstrates the dilution linearity and was close to expected levels (within normal 
variance for analysis methods). 
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Pilot study 2 was conducted to further assess the ability of the anti-PA ELISA to 
detect the human IgG.  In this study three positive materials were compared to determine 
any differences between the purified AIG, the source plasma for the purified AIG 
(BMI505), and a well characterized known positive human serum.  The results presented 
in Tables 16-18 (pp. 44-45) were less consistent than the results in the initial pilot study.  
The mean recoveries across dilution factors and diluents were similar for the AIG and 
AVA plasma (BMI505) demonstrating that the purification process had negligible affects 
on the anti-PA IgG within the material.  Overall the second pilot study supported the 
conclusion from the first pilot study that the ELISA assay (when processed with human 
reagents) has the ability to consistently detect the human anti-PA in both naïve and 
positive rabbit sera.  
The ELISA assays were performed on the rabbit sera samples following the 
passive administration of the test and control articles at 1, 24, 48, 72, 96 h, 7, 10, 13, 16, 
19, 22, 25, and 28 days.  In order to accurately determine the half-life (t ½) of the AIG 
material the t ½ for each dilution (groups 1-3) was averaged.  The t ½ of the material was 
calculated to be 4.3 days with a standard deviation of 0.06.  The peak serum 
concentration was observed at 24 h (+/-15 min) post-administration for all test groups.  
The serum concentration for group 4 never exceeded the assay’s LOQ, indicating no anti-
PA activity present in the naïve human IgG. 
While the test material afforded no protection against the lethal B. anthracis 
aerosol challenge, the study achieved its primary goal.  There is an accurate assessment 
of the half-life of the AIG material.  This allows for future work to focus on the window 
of opportunity for prophylaxis and treatment against a lethal inhalation challenge.  Future 
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work can assess the protection efficacy of passively administered antibodies against an 
inhalation challenge when serum is at peak concentrations (24 h post-treatment).  
Furthermore, future work could investigate passively transferred IgG as a treatment post 
challenge.  The knowledge that the AIG material causes no lethal toxicity will allow for 
this work to move forward without concerns of adverse effects on the study animals.    
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